|Body Surface Area (m2)||0.007||0.025||0.15||0.05||0.02||0.5|
|Animal A (mg/kg) = Animal B (mg/kg) multiplied by||Animal B Km|
|Animal A Km|
For example, to modify the dose of Compound A used for a mouse (20 mg/kg) to a dose based on the BSA for a rat, multiply 20 mg/kg by the Km factor for a mouse and then divide by the Km factor for a rat. This calculation results in a rat equivalent dose for Compound A of 10 mg/kg.
 Torsten Hoffmann, et al. Int J Mol Sci. Combination of the Glutaminyl Cyclase Inhibitor PQ912 (Varoglutamstat) and the Murine Monoclonal Antibody PBD-C06 (m6) Shows Additive Effects on Brain Aβ Pathology in Transgenic Mice
 E G B Vijverberg, et al. Alzheimers Res Ther. Rationale and study design of a randomized, placebo-controlled, double-blind phase 2b trial to evaluate efficacy, safety, and tolerability of an oral glutaminyl cyclase inhibitor varoglutamstat (PQ912) in study participants with MCI and mild AD-VIVIAD
L-2-Aminooxy-3-phenylpropanoic acid is an inhibitor of L-phenylalanine ammonia-lyase.
Diphenyl diselenide inhibits δ-aminolevulinic acid dehydrase (δ-ALA-D) in brain, liver, and kidney in vivo.
BAY-069 is a branched-chain amino acid transaminase (BCAT) 1/2 inhibitor. Involved in the synthesis and catabolism of branched-chain amino acids.
UCB7362 is an oral plasma protease X (PMX) inhibitor that is being developed as an anti-malarial compound.
AN15368 is an oral cleavage and polyadenylate specific factor (CPSF3) inhibitor being developed for use in Chagas disease (also known as American trypanosomiasis).
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2020 AbMole BioScience. All Rights Reserved.